Reduced CYP2C19 activity in cancer patients

M. L. Williams, P. Bhargava, J. L. Marshall, D. A. Flockhart, I. W. Wainer

Research output: Contribution to journalArticle

Abstract

A discordance between individual genotypes for cytochrome P450 2C19 (CYP2C19) and expressed CYP2C19 phenotypes has been observed in 16 Caucasian patients with advanced cancer. CYP2C19 genotypes were determined by PCR-based amplification followed by restriction fragment length analysis. CYP2C19 phenotypes were determined using log omeprazole hydroxylation index. All 16 patients were found to have an EM genotype, which was expected since only 3% of Caucasians possess a PM geno-type for CYP2C19. However, 4 of the patients (25%) were found to have PM phenotypes. The remaining 12 patients also displayed a statistically significant shift towards the PM phenotype, relative to results from healthy volunteers (P=0.002, Wilcoxon Signed-Rank test). None of the 16 patients were receiving any known CYP2C19 inhibitors at the time of phenotyping and there were no likely drug interactions. The 4 patients whose genotype and phenotype were discordant were all suffering from metastasized adenocarcinomas. No two patients had received the same anticancer therapy and therefore, no one drug could be identified as the source of the observed EM to PM transition. In conclusion, such changes in CYP2C19 activity could have a considerable impact on the clinical efficacy and toxicity of therapeutic agents.

Original languageEnglish (US)
Pages (from-to)196
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume65
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Cytochrome P-450 Enzyme System
Phenotype
Genotype
Neoplasms
Omeprazole
Hydroxylation
Nonparametric Statistics
Drug Interactions
Healthy Volunteers
Adenocarcinoma
Polymerase Chain Reaction
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Williams, M. L., Bhargava, P., Marshall, J. L., Flockhart, D. A., & Wainer, I. W. (1999). Reduced CYP2C19 activity in cancer patients. Clinical Pharmacology and Therapeutics, 65(2), 196.

Reduced CYP2C19 activity in cancer patients. / Williams, M. L.; Bhargava, P.; Marshall, J. L.; Flockhart, D. A.; Wainer, I. W.

In: Clinical Pharmacology and Therapeutics, Vol. 65, No. 2, 1999, p. 196.

Research output: Contribution to journalArticle

Williams, ML, Bhargava, P, Marshall, JL, Flockhart, DA & Wainer, IW 1999, 'Reduced CYP2C19 activity in cancer patients', Clinical Pharmacology and Therapeutics, vol. 65, no. 2, pp. 196.
Williams ML, Bhargava P, Marshall JL, Flockhart DA, Wainer IW. Reduced CYP2C19 activity in cancer patients. Clinical Pharmacology and Therapeutics. 1999;65(2):196.
Williams, M. L. ; Bhargava, P. ; Marshall, J. L. ; Flockhart, D. A. ; Wainer, I. W. / Reduced CYP2C19 activity in cancer patients. In: Clinical Pharmacology and Therapeutics. 1999 ; Vol. 65, No. 2. pp. 196.
@article{550b282025bb471db4f0ab4205a02694,
title = "Reduced CYP2C19 activity in cancer patients",
abstract = "A discordance between individual genotypes for cytochrome P450 2C19 (CYP2C19) and expressed CYP2C19 phenotypes has been observed in 16 Caucasian patients with advanced cancer. CYP2C19 genotypes were determined by PCR-based amplification followed by restriction fragment length analysis. CYP2C19 phenotypes were determined using log omeprazole hydroxylation index. All 16 patients were found to have an EM genotype, which was expected since only 3{\%} of Caucasians possess a PM geno-type for CYP2C19. However, 4 of the patients (25{\%}) were found to have PM phenotypes. The remaining 12 patients also displayed a statistically significant shift towards the PM phenotype, relative to results from healthy volunteers (P=0.002, Wilcoxon Signed-Rank test). None of the 16 patients were receiving any known CYP2C19 inhibitors at the time of phenotyping and there were no likely drug interactions. The 4 patients whose genotype and phenotype were discordant were all suffering from metastasized adenocarcinomas. No two patients had received the same anticancer therapy and therefore, no one drug could be identified as the source of the observed EM to PM transition. In conclusion, such changes in CYP2C19 activity could have a considerable impact on the clinical efficacy and toxicity of therapeutic agents.",
author = "Williams, {M. L.} and P. Bhargava and Marshall, {J. L.} and Flockhart, {D. A.} and Wainer, {I. W.}",
year = "1999",
language = "English (US)",
volume = "65",
pages = "196",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Reduced CYP2C19 activity in cancer patients

AU - Williams, M. L.

AU - Bhargava, P.

AU - Marshall, J. L.

AU - Flockhart, D. A.

AU - Wainer, I. W.

PY - 1999

Y1 - 1999

N2 - A discordance between individual genotypes for cytochrome P450 2C19 (CYP2C19) and expressed CYP2C19 phenotypes has been observed in 16 Caucasian patients with advanced cancer. CYP2C19 genotypes were determined by PCR-based amplification followed by restriction fragment length analysis. CYP2C19 phenotypes were determined using log omeprazole hydroxylation index. All 16 patients were found to have an EM genotype, which was expected since only 3% of Caucasians possess a PM geno-type for CYP2C19. However, 4 of the patients (25%) were found to have PM phenotypes. The remaining 12 patients also displayed a statistically significant shift towards the PM phenotype, relative to results from healthy volunteers (P=0.002, Wilcoxon Signed-Rank test). None of the 16 patients were receiving any known CYP2C19 inhibitors at the time of phenotyping and there were no likely drug interactions. The 4 patients whose genotype and phenotype were discordant were all suffering from metastasized adenocarcinomas. No two patients had received the same anticancer therapy and therefore, no one drug could be identified as the source of the observed EM to PM transition. In conclusion, such changes in CYP2C19 activity could have a considerable impact on the clinical efficacy and toxicity of therapeutic agents.

AB - A discordance between individual genotypes for cytochrome P450 2C19 (CYP2C19) and expressed CYP2C19 phenotypes has been observed in 16 Caucasian patients with advanced cancer. CYP2C19 genotypes were determined by PCR-based amplification followed by restriction fragment length analysis. CYP2C19 phenotypes were determined using log omeprazole hydroxylation index. All 16 patients were found to have an EM genotype, which was expected since only 3% of Caucasians possess a PM geno-type for CYP2C19. However, 4 of the patients (25%) were found to have PM phenotypes. The remaining 12 patients also displayed a statistically significant shift towards the PM phenotype, relative to results from healthy volunteers (P=0.002, Wilcoxon Signed-Rank test). None of the 16 patients were receiving any known CYP2C19 inhibitors at the time of phenotyping and there were no likely drug interactions. The 4 patients whose genotype and phenotype were discordant were all suffering from metastasized adenocarcinomas. No two patients had received the same anticancer therapy and therefore, no one drug could be identified as the source of the observed EM to PM transition. In conclusion, such changes in CYP2C19 activity could have a considerable impact on the clinical efficacy and toxicity of therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=33749094707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749094707&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749094707

VL - 65

SP - 196

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -